key: cord-312984-rzryn3on
authors: Pan, Daniel; Sze, Shirley; Rogers, Benedict; Bron, Jan; Bird, Paul W.; Holmes, Christopher W.; Tang, Julian W.
title: Serial simultaneously self-swabbed samples from multiple sites show similarly decreasing SARS-CoV-2 loads in COVID-19 cases of differing clinical severity
date: 2020-09-19
journal: J Infect
DOI: 10.1016/j.jinf.2020.09.016
sha: 
doc_id: 312984
cord_uid: rzryn3on

nan

Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for diagnosis of Coronavirus disease . Nasopharyngeal swabs (NPS) are recommended by the World Health Organisation (WHO) as the current standard method to detect SARS-CoV-2 in suspected patients. 1 However, collection of an NPS or oropharyngeal swab (OPS) can be technically difficult, uncomfortable for patients, may induce sneezing or coughing, and expose those nearby to aerosolised SARS-CoV-2). 2 We postulate that alternative easier-to-sample swabs such as those from the nose (NS) or cheek (CS) may be equally sensitive in acute COVID-19 cases, and can be effectively taken by patients themselves. In addition, longitudinal analysis of serial samples collected contemporaneously from multiple upper respiratory tract (URT) sites, from the same patient, has not been well described. Here, we performed a prospective longitudinal analysis of three healthcare worker volunteers with differing clinical severities of acute COVID-19.

Shortly after a confirmed diagnosis of COVID-19 using the local diagnostic AusDiagnostics (Ausdiagnostics UK Ltd., Chesham, England) SARS-CoV-2 PCR test, 3 each participant volunteered to provide serial self-collected swabs from the nasopharynx (NPS, 1 swab), just inside the soft part of the nose (NS, 1 swab), the oropharynx (OPS, 1 swab), inside the cheek (CS, 1 swab). In addition, we also decided to check for the presence of SARS-CoV-2 in the conjunctiva (CJS, 1 swab for both eyes). All of these swabs were taken at the same time-point, on a daily basis -or as frequently as was practical and tolerable -until all the SARS-CoV-2 viral loads became undetectable. Thus, each patient collected up to 5 separate swabs on a daily basis for this study.

All three participants (hereafter referred to individually as 'Patient' 1, 2, or 3) became symptomatic with confirmed COVID-19 during the week of 12th April 2020. Patient 1 had mild COVID-19, complaining of a 7-day history of anosmia only; Patient 2 had moderate COVID-19, with a 5-day history of fevers, shivers, dry cough and myalgia; Patient 3 had severe COVID-19, presenting with a 2-week history of fevers, shivers and a productive cough that required supplemental oxygen therapy, and eventual admission to the intensive care unit (ICU) during the second week, after which no further swabs were taken. Final follow-up swabs were performed by the participants on 5th May 2020, two weeks after symptom onset for all participants.

From 17th April to 5th May 2020, a total of 105 swabs were collected from three participants ( Our small longitudinal study cohort demonstrated several findings. Firstly, the most symptomatic case, Patient 3 was most likely to be viremic at multiple sites in the URT, as reported elsewhere. 4 Secondly, self-swabbing from these various URT sites is an effective and sensitive way to collect diagnostic samples, as found elsewhere. 5 Note that only one out of these three cases, Patient 3 who did not exhibit overt conjunctivitis, exhibited detectable virus from the conjunctiva within the first 5 days of illness. Patient 1 s first swab was only taken on Day 8 post-illness onset, so it is possible that any virus present earlier in conjunctival fluids may have been missed. However, this lower detection rate for conjunctival swabs (with or without overt conjunctivitis) is consistent with previous reports. 6 Thirdly, the relative SARS-CoV-2 viral loads from the URT decreased with time in the 1-2 weeks post-COVID-19 symptom onset, regardless of disease severity. This has been shown elsewhere, 7 though this is not always the case. 8 From this small longitudinal cohort study on serially collected samples in acute COVID-19 cases of differing severity, we conclude that for symptomatic patients, it is difficult to obtain a 'false negative' result on NPS, OPS, NS or CS samples, if sampled early (within 5 days) post-symptom onset, even if the swab was 'poorly' taken. Despite a previous meta-analysis showing that sputum testing is possibly more sensitive for SARS-CoV-2 PCR testing, 9 other studies have shown that self-sampling from various URT sites performed satisfactorily for the diagnosis of acute COVID-19. 5 Sputum testing is not standard in many virology labs due to long-recognised problems related to its viscosity and risks of PCR inhibition, 10 and not all COVID-19 patients will have a productive cough.

Therefore, we further confirm that early (within 5 days of symptom onset), self-swabbed NPS, OPS, NS or CS samples for SARS-CoV-2 diagnostic testing in acute COVID-19 cases is a sensitive, practical approach, which reduces patient discomfort (as self-swabbing can be controlled) and minimises virus exposure to healthcare workers.

WHO. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases 2020

How to obtain a nasopharyngeal swab specimen

High SARS-CoV-2 infection rates in respiratory staff nurses and correlation of COVID-19 symptom patterns with PCR positivity and relative viral loads

Virological assessment of hospitalized patients with COVID-2019

Swabs collected by patients or health care workers for SARS-CoV-2 testing

Detecting SARS-CoV-2 RNA in conjunctival secretions: is it a valuable diagnostic method of COVID-19?

SARS-CoV-2 Viral Load in upper respiratory specimens of infected patients

YJINF [m5G

Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility

SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis

Comparison of sputum and nasopharyngeal swabs for detection of respiratory viruses


